Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics Inc (NASDAQ:STOK) is set to release its Q2 2025 earnings on Aug 12, 2025. The consensus estimate for Q2 ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

Wrexham striker Ollie Palmer has scored two goals in the space of a minute in stoppage time then converted one of the team’s ...

Has striker Ollie Palmer just earned himself the most unlikely of Wrexham reprieves with two goals against Hull City?

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

STOK, the landmark 60,000 sq ft office building in Stockport, has completed the fit out of its final phase of 'plug and play' ...

Wrexham forward Ryan Hardie says he apologised to his team-mates for missing a "crucial" chance at Southampton that might ...

Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning ...

Located near Openshaw Park and close to key amenities, the development offers a mix of two-bedroom apartments and ...

Phil Parkinson remains determined to further bolster his Wrexham squad but insists players already at the club will be given ...

Stumptown reigns supreme in the cold brew world, setting the gold standard that other brands aspire to match. Their ...